Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib.
Nearly 30% of corresponding authors included in the analysis shared that they had witnessed scientific fraud in their department within the last five years.
A well-known cardiologist who once fully supported COVID-19 vaccines is now saying he thinks they have done more harm than good. Online, as one might expect, people on both sides of this particular debate have been quick to respond.
Researchers have received a five-year grant worth $30 million to study how a new-look physical rehab program impacts outcomes among older HFpEF patients.
Diabetes and atrial fibrillation are just some of the factors that can increase a patient's risk of being hospitalized for heart failure within one year of undergoing a successful TAVR procedure.
An AI startup in the neuro-oncology space has received the government’s go-ahead to market software for analyzing certain fast-growing brain tumors on MRI.
If generalizable AI models are to meaningfully contribute to precision cancer care, they’ll need to incorporate not only imaging data but also digitalized clinical notes, biomarker assays and monitor readouts.
